NCT06621199View on ClinicalTrials.gov

Mitoxantrone Hydrochloride Liposome in Combination With Cytarabine and Venetoclax Regimen in Newly Diagnosed Elderly AML

PHASE2RecruitingINTERVENTIONAL
Enrollment

42

Participants

Timeline

Start Date

July 8, 2024

Primary Completion Date

December 31, 2027

Study Completion Date

December 31, 2027

Conditions
Acute Myeloid Leukemia
Interventions
DRUG

Mitoxantrone hydrochloride liposome

Mitoxantrone hydrochloride liposome 24 mg/m\^2 on day 1, every 4 weeks

DRUG

Cytarabine

Cytarabine 100 mg/m\^2 on day 1-5, every 4 weeks

DRUG

Venetoclax

Venetoclax 100 mg on day 2，200 mg on day 3，400 mg on day 4-10, every 4 weeks

Trial Locations (1)

310003

RECRUITING

The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou

All Listed Sponsors
collaborator

CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd.

INDUSTRY

lead

First Affiliated Hospital of Zhejiang University

OTHER